Senior Consultant Akkeri, Inc. Annandale, New Jersey, United States
This presentation will provide a general overview of this field to introduce basic concepts necessary for understanding subsequent specific topics. Material will include the importance and utility of biomarkers for neurotoxicity, different biomarker modalities such as body fluid samples (blood, plasma/serum, CSF), imaging, and histopathology across differing therapeutic indications. Biomarker issues differ between a neurodegenerative disease and non-degenerative genetic disorder and are further complicated by treatment modalities potentially causing some degree of neurotoxicity. A brief example will be discussed involving a lack of correlation between two high-value neurotoxicity indices with respect to AAV-based gene therapy.
